Amgen (NASDAQ:AMGN) executives highlighted broad-based commercial momentum, a focus on long-term growth drivers, and several ...

Amgen (NasdaqGS:AMGN) and Kyowa Kirin have stopped all clinical trials of rocatinlimab after newly identified safety concerns. The companies cited potential links between OX40 pathway modulation and ...

Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference at 9:20 a.m. ET on Wednesday, March 11, 2026. Peter Griffith, executive vice president and chief financial ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Amgen reaches a fresh annual peak amid strong quarterly performance and renewed institutional accumulation. Major research firms revise price targets following operational outperformance and margin ...

Amgen Inc. has reached a significant milestone as its stock hit an all-time high of 385.63 USD, with shares currently trading at $386.08, just shy of the 52-week high of $385.12.

Amgen Inc. (NASDAQ:AMGN) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Amgen Inc. (NASDAQ:AMGN) was downgraded to Hold from Buy by Freedom Capital, with the ...

Infrastructure and location have helped make Holly Springs a future hub for obesity drug production, with Amgen and Roche ...

The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients, which ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the second quarter of 2026. The dividend will be paid on June 5, 2026, to all stockholders of ...

Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IRS.